Introduction
tumor, breast cancer, TNBC, mTNBC, chemotherapy-induced damage
TRIPLE-NEGATIVE BREAST CANCER, TUMOR, INVASIVE BREAST CANCER, BREAST CANCER
Triple-negative breast cancer (TNBC) is a specific subtype of breast cancer that is associated with high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. Patients with TNBC have fewer treatment options available to them than those with other types of invasive breast cancer [Trilaciclib is an intravenous myeloprotection therapy that is administered as a 30-min infusion within 4 h prior to the start of chemotherapy on each day chemotherapy is administered. Trilaciclib transiently arrests cyclin-dependent kinase 4/6 (CDK4/6)-dependent hematopoietic stem and progenitor and immune cells in the G1 phase of the cell cycle during chemotherapy exposure, protecting these cells from chemotherapy-induced damage [Trilaciclib has been shown to favorably alter the tumor immune microenvironment in in vivo murine syngeneic models [The efficacy and safety of trilaciclib in patients with mTNBC have been investigated in a randomized phase II trial (NCT02978716) [The aim of the current analysis was to further investigate potential immune mechanisms of trilaciclib in mTNBC through the analysis of immune cell subsets and molecular profiling in peripheral blood and tumor samples, respectively.